

Prevention and reversal of pulmonary inflammation and airway hyperresponsiveness by dexamethasone treatment in a murine model of asthma induced by house dust

Jiyoun Kim, Laura McKinley, Javed Siddiqui, Gerry L. Bolgos, and Daniel G. Remick

Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48103-0602

Submitted 3 December 2003; accepted in final form 30 April 2004

Kim, Jiyoun, Laura McKinley, Javed Siddiqui, Gerry L. Bolgos, and Daniel G. Remick. Prevention and reversal of pulmonary inflammation and airway hyperresponsiveness by dexamethasone treatment in a murine model of asthma induced by house dust. *Am J Physiol Lung Cell Mol Physiol* 287: L503–L509, 2004. First published May 7, 2004; 10.1152/ajplung.00433.2003.—The morbidity and mortality from asthma in the Western world have increased 75% in the past 20 years. Recent studies have demonstrated that sensitization to cockroach allergens correlates strongly with the increased asthma morbidity for adults and children. We investigated whether dexamethasone administered before or after allergen challenge would inhibit the pulmonary inflammation and airway hyperresponsiveness in a mouse model of asthma induced by a house dust extract with high levels of cockroach allergens. For the prevention experiment, mice were treated with an intraperitoneal injection of dexamethasone 1 h before each pulmonary challenge, and airway hyperresponsiveness was measured 24 h after the last challenge. Mice were killed 48 h after the last challenge. For the reversal study, airway hyperresponsiveness was measured 24 h after the last challenge, and the mice were treated with dexamethasone. Dexamethasone treatment before allergen challenge significantly reduced the pulmonary recruitment of inflammatory cells, myeloperoxidase activity in the lung, airway hyperreactivity, and total serum IgE levels compared with PBS-treated mice. Additionally, dexamethasone treatment could significantly reduce the airway hyperreactivity of an established asthmatic response. These results demonstrate that dexamethasone not only prevents but also halts the asthmatic response induced by house dust containing cockroach allergens. This model exhibits several features of human asthma that may be exploited in the study of pathophysiological mechanisms and potential therapeutic interventions.

corticosteroids; eosinophils; neutrophils; airway hyperreactivity; IgE

ASTHMA IS A UNIQUE FORM of chronic airway inflammation characterized by reversible airway obstruction, inflammatory mediator production, and airway hyperresponsiveness (AHR) (34). After exposure to allergens, the airway is infiltrated with a variety of inflammatory cells, including lymphocytes, macrophages, neutrophils, and eosinophils. Among these, eosinophils are the predominant effector cells for tissue damage and pulmonary dysfunction (34, 41). Furthermore, the intensity of pulmonary recruitment of eosinophils correlates strongly with the severity of AHR (18, 21, 48).

Once eosinophils have infiltrated the lung, numerous inflammatory changes in the airways are triggered, including the release of a wide variety of immunomodulator molecules such as major basic protein (35, 41). The localization of eosinophils

to the bronchial mucosa potentially primes the lung for subsequent immune responses and augments allergic pulmonary inflammation by the secretion of various cytokines (8, 34). Selective recruitment of eosinophils into the airways during allergic inflammation suggests that eosinophil-specific chemoattractants are produced and released throughout the course of pulmonary inflammation. The C-C chemokine eotaxin is considered the major eosinophil chemoattractant in animal models of eosinophilic pulmonary inflammation (17, 36) and in human tissues (15, 31) after allergen sensitization.

An increase in AHR in response to a methacholine challenge has been demonstrated as a diagnostic sign of asthma in various animal models of asthma (48). Enhanced pause (Penh) from whole body plethysmography in unrestrained and conscious animals represents a widely used measure of AHR, and such changes are strongly correlated with pulmonary recruitment of inflammatory cells in asthmatic animals (19).

Glucocorticoids are currently the most effective treatment for asthma with proven effectiveness and safety (40, 43), and the efficacy of these agents has been demonstrated in the prevention of asthma morbidity and mortality (43). Routine use of glucocorticoids as a prophylactic measure of asthma has improved disease outcomes, including reduced hospitalizations (47). Furthermore, early treatment of acute asthma with systemic administration of corticosteroids for emergency department patients has dramatically reduced the need for hospitalization, prevented relapse, and expedited recovery, especially for patients with severe asthma and for children (37, 38).

Various mouse models of asthma have been developed for studying the inflammatory mechanisms of asthma (5). To induce allergic asthma-like pulmonary inflammation in healthy animals, it was necessary to sensitize and challenge with specific allergens. Among them, ovalbumin (13, 20) and purified indoor allergens such as cockroach (9, 49) and dust mite (11, 44) are commonly used allergens in murine asthma models. However, in terms of quality and quantity of allergens, the allergens used for these animal models may not represent exactly the same constituents to which asthmatics are exposed throughout their daily lives. To date, very few environmental allergens collected directly from houses have been used to develop animal models of asthma-like pulmonary inflammation (24). We have developed a novel murine model of allergic pulmonary inflammation (24) that shows AHR, bronchopulmonary recruitment of inflammatory cells, and pulmonary expression of chemokines following house dust extract immunization and challenge.

Address for reprint requests and other correspondence: J. Kim, M2210 Med Sci I, 1301 Catherine Rd., Ann Arbor, MI 48109-0602 (E-mail: jiyounkim@umich.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This model may be exploited further to examine therapeutic modalities to treat asthma. As a first step in this investigation, we sought to determine whether a classic treatment option for acute asthma, glucocorticoids, would prevent or break an asthmatic response in this model. The animals were treated with the glucocorticosteroid dexamethasone before or after the onset of an asthmatic response to determine the effects of corticosteroids in the pulmonary infiltration of inflammatory cells and bronchopulmonary hyperresponsiveness.

MATERIALS AND METHODS

Mice

Female BALB/c mice (18–20 g) were obtained from Harlan Sprague-Dawley (Indianapolis, IN) and maintained under standard laboratory conditions. The mice were housed in a temperature-controlled room (22°C) with a 12:12-h light-dark cycle with food and water allowed ad libitum. All experiments were performed in accordance with the National Institutes of Health guidelines and approved by the University of Michigan Animal Use Committee.

Experiment Design

The household dust used for all sensitizations and airway challenges was collected from a house in Detroit, MI, and then extracted as we previously reported (24). Briefly, a total of 4.3 g of house dust was collected from the house and extracted with 30 ml of sterile PBS. This house dust extract was assayed for nine different allergens including six indoor and three outdoor allergens: German cockroach (*Blattella germanica*, Bla g1 and Bla g2), house dust mite (*Dermatophagoides pteronyssinus* Der p1, and *Dermatophagoides farinae* Der f1), cat (*Felis domesticus*, Fel d1), and dog (*Canis familiaris*, Can f1), meadow fescue (*Festuca pratensis*), short ragweed (*Ambrosia artemisiifolia*), and mold (*Alternaria alternata*). Our house dust extract contained very high concentrations of cockroach allergens (378 U/ml Bla g1 and 6,249 ng/ml Bla g2), whereas four other indoor allergens and all three outdoor allergens were very low (data not shown). The house dust extract contained 270 pg/ml of endotoxin. We used this aqueous house dust extract (diluted 1:10) for immunization and intratracheal instillation as previously described (24). Briefly, mice were sensitized by an intraperitoneal injection of 50 μ l of house dust extract mixed with an adjuvant (TiterMax Gold; CytRx, Norcross, GA) for a total volume of 100 μ l on day 0 (Fig. 1). On days 14 and 21, mice were given a pulmonary challenge of 50 μ l of house dust extract (27). For controls, normal female BALB/c mice were also examined. These mice were not immunized or challenged.

Dexamethasone Treatment

For the prevention study, immunized mice were treated with 2.5 mg/kg body wt of water-soluble dexamethasone (catalog no. D 2915; Sigma, St. Louis, MO) in PBS by intraperitoneal injection 1 h before each pulmonary challenge on days 14 and 21 (Fig. 1). Control mice received 0.2 ml of PBS.

For the reversal study, mice were immunized and challenged twice on days 14 and 21. Twenty-four hours after the last challenge (day 22), AHR was measured, and the mice received an intraperitoneal injection of dexamethasone (2.5 mg/kg) immediately afterward (Fig. 1). Another AHR was measured 12 h and again 24 h after dexamethasone administration.

Determination of AHR

Twenty-four hours after the final challenge, AHR was measured for both the prevention and the reversal studies, as described in our previous publication (24). AHR was again measured 12 and 24 h after dexamethasone administration (36 and 48 h after the last allergen




Fig. 1. Experiment protocols. Groups of female BALB/c mice received 1 immunization (day 0) and 2 intratracheal challenges (days 14 and 21) with 50 μ l of house dust extract. For the prevention study, mice received dexamethasone (Dexa) treatment 1 h before each intratracheal challenge by intraperitoneal injection. Airway hyperresponsiveness (AHR) was measured 24 h after the last pulmonary challenge, and mice were killed 24 h after AHR measurement (48 h after the last challenge). For the reversal study, mice did not receive Dexa treatment with the pulmonary challenge but were treated with Dexa after the first AHR was measured. Additional measurements of AHR were performed 12 and 24 h after the Dexa treatment. Mice were killed immediately after the last AHR was measured (48 h after the last challenge).

challenge, respectively) in the reversal experiment. Changes in early expiration due to bronchoconstriction were measured and expressed as Penh, which is a main indicator of airway obstruction. Airway resistance of the animal is strongly correlated with Penh and is widely accepted in murine asthma models (19). Airway responsiveness was expressed as a percent increase of Penh for each concentration of methacholine compared with Penh for PBS challenge. Increasing doses of aerosolized acetyl β -methylcholine (Sigma) were delivered for 2 min, and the response to each dose was measured for 5 min by a whole body plethysmography system (Buxco, Troy, NY) as previously reported (24).

Sample Collection and Analysis

Forty-eight hours from the last airway challenge (day 23), the mice were killed for collection of blood, bronchoalveolar lavage, and histological examination as described in our previous report (24). An analysis of total IgE in mouse plasma was performed by ELISA, and the IgE standard curve was used for calculation of total IgE concentrations. We assayed the total serum IgE concentration, since a standard for cockroach allergen-specific IgE is not available.

For the myeloperoxidase assay, the right lung was removed and processed as described previously (27). Even though it is important to discriminate between eosinophils and neutrophils in the inflammatory reaction, especially in asthma (39), our myeloperoxidase assay of lung tissue homogenates detected peroxidase from neutrophils and eosinophils.

Statistical Analyses

Means $\pm$ SE were used for summary statistics in all figures. Differences between all treatment groups were compared by ANOVA. Tukey's test for pairwise comparisons was performed when the overall *F* value was statistically significant (*P* < 0.05).




Fig. 2. Dexa decreases bronchoalveolar lavage inflammatory cell numbers. BALB/c mice received 1 immunization and 2 pulmonary challenges with the house dust extract. Mice were treated with systemic Dexa (2.5 mg/kg) or PBS 1 h before each pulmonary challenge, or treatment. We performed all cell counts 48 h after the last challenge and cell differentials by counting 300 cells. Values represent means $\pm$ SE with $n = 8$ for Dexa or PBS group and $n = 3$ for normal. * $P < 0.05$ or ** $P < 0.01$ compared with PBS treated.

RESULTS

Effects of Dexamethasone as a Preventative Measure

Pulmonary recruitment of inflammatory cells. In an effort to demonstrate whether corticosteroid treatment can modify the pathophysiology of asthma in a novel murine model, BALB/c mice were immunized once and challenged twice intratracheally with a house dust extract containing high concentrations of cockroach allergens (Bla g1, 37.8 U/ml; Bla g2, 625 ng/ml). Mice received a single dexamethasone treatment 1 h before each challenge and were killed 48 h after the last challenge. The house dust extract induced inflammatory cell infiltration in the bronchoalveolar lavage. The numbers of inflammatory cells in the bronchoalveolar lavage, including eosinophils, macrophages, and neutrophils in the dexamethasone-treated mice were significantly lower than those in PBS-treated mice (Fig. 2). However, dexamethasone did not decrease the number of bronchoalveolar lavage lymphocytes (data not shown). The effect of dexamethasone on pulmonary recruitment of inflammatory cells in this model was further evaluated by measurement of pulmonary myeloperoxidase activity (Fig. 3). The neutrophil and eosinophil activity within the lung tissue detected by the myeloperoxidase assay was dramatically reduced in dexamethasone-treated mice ($P = 0.001$) when compared with PBS-treated mice.

Systemic effects. We then ascertained whether the plasma IgE concentration was affected by systemic corticosteroid therapy. As seen in Fig. 4, total plasma IgE levels in dexamethasone-treated mice were substantially lower ($P < 0.001$) than levels in mice treated with PBS. In an effort to confirm that plasma expression of IgE is modified by dexamethasone treatment itself, we investigated the plasma IgE levels in three groups of mice: the mice immunized with house dust that received the dexamethasone treatment, the mice immunized with house dust that received the PBS treatment, and normal mice. There were no significant differences among three mice groups (data not shown). We also examined the changes in circulating blood cell counts, and no significant differences were observed between dexamethasone-treated mice and PBS-treated mice (data not shown).

Modification of AHR. We evaluated the effects of dexamethasone on bronchopulmonary hyperreactivity in house dust extract-immunized mice by measuring Penh via whole body plethysmography. Immunized BALB/c mice were treated with dexamethasone 1 h before each intratracheal challenge on days 14 and 21. AHR in response to aerosolized methacholine was measured 24 h after the last pulmonary challenge (Fig. 5). Dexamethasone treatment significantly reduced bronchopulmonary hyperresponsiveness when compared with PBS treatment ($P < 0.04$ at 25 and 50 mg/ml methacholine challenge).

Effects of Dexamethasone on Acute Asthma Attack

Glucocorticoids are frequently used for treatment of an acute asthmatic attack, i.e., the drug is given after the onset of symptoms. Therefore, we investigated whether glucocorticosteroid treatment after the onset of an asthma attack can reduce the severity of bronchopulmonary hyperresponsiveness and pulmonary recruitment of inflammatory cells in our model.




Fig. 3. Dexa decreases pulmonary myeloperoxidase (MPO) activity. BALB/c mice were immunized and challenged with the house dust extract. Mice received systemic Dexa (2.5 mg/kg) or PBS 1 h before each pulmonary challenge and were killed 48 h after the last challenge. Normal mice did not receive any immunization, pulmonary challenge, or treatment. After bronchoalveolar lavage fluid was collected, the right lung was removed and immediately processed for the assay. Values represent means $\pm$ SE with $n = 8$ for Dexa or PBS group and $n = 3$ for normal. *** $P < 0.001$ compared with PBS treated and †† $P < 0.01$ compared with normal.




Fig. 4. Dexa decreases plasma levels of total IgE in house dust extract-sensitized and -challenged BALB/c mice. Mice received systemic Dexa (2.5 mg/kg) or PBS 1 h before each pulmonary challenge. Normal mice did not receive any immunization, pulmonary challenge, or treatment. Blood was collected 48 h after the last intratracheal challenge. Values represent means $\pm$ SE with $n = 8$ for Dexa or PBS group and $n = 3$ for normal. $**P < 0.01$ compared with PBS treated and $\dagger P < 0.05$ compared with normal.

Mice were immunized and then challenged twice with the house dust extract. Twenty-four hours after the last challenge, we measured AHR via whole body plethysmography. Immediately after measuring AHR, we treated one group of mice with dexamethasone while giving the control group PBS treatment. Twelve hours after the dexamethasone administration, we again measured AHR to investigate whether dexamethasone could reduce the severity of asthma attack. As shown in Fig. 6A, there is no significant difference between the two groups of BALB/c mice before dexamethasone treatment. However, as shown in Fig. 6B, dexamethasone treatment significantly reduced bronchopulmonary hyperreactivity ($P < 0.05$ at 25 and 50 mg/ml methacholine) within 12 h. This effect of dexamethasone on AHR was no longer present 24 h after administration (Fig. 6C). In addition, the number of neutrophils infiltrated into the airway in dexamethasone-treated group was significantly higher than in PBS-treated ($P = 0.036$), whereas the number of macrophages and eosinophils was lower when compared with PBS-treated mice (Fig. 7).




Fig. 5. AHR in Dexa- or PBS-treated mice. The Dexa (2.5 mg/kg) or PBS was administered systemically 1 h before each challenge. Normal mice did not receive any immunization, pulmonary challenge, or treatment. Enhanced pause (Penh) values were obtained from mice 24 h after the last challenge in response to nebulized methacholine via whole body plethysmography. The data are expressed as means $\pm$ SE of Penh values ($n = 8$ for Dexa or PBS and $n = 3$ for normal) as the increased percentage of baseline observed after PBS nebulization. $*P < 0.05$ compared with PBS-treated group.




Fig. 6. Dexa breaks AHR after the onset of the asthmatic response. Groups of BALB/c mice were immunized and challenged with house dust extract. Normal mice did not receive any immunization, pulmonary challenge, or treatment. Twenty-four hours after the last challenge, AHR was measured (A). Immediately after the AHR, mice were treated with either systemic Dexa (2.5 mg/kg) or PBS. Twelve and twenty-four hours after the treatment, the second (B) and the third AHR were measured, respectively. The data are expressed as means $\pm$ SE of Penh values ($n = 8$) as the increased percentage above baseline observed after PBS nebulization. The data for the normal mice were obtained from 1 time point and used for all 3 panels. $*P < 0.05$ compared with PBS-treated group.

DISCUSSION

Currently glucocorticoids, either inhaled or systemically delivered, are the most effective anti-inflammatory drugs in the treatment of asthma and are widely recommended as first-line therapy for this disease (1, 7). Regular use of corticosteroids has been shown to significantly reduce the mortality and morbidity of asthma (43).

Glucocorticosteroid suppression of inflammation occurs via inhibition of multiple aspects of the inflammatory process that include an increase in the expression of anti-inflammatory genes and proteins, as well as a decrease in the expression of




Fig. 7. Dexa alters airway infiltration of inflammatory cells after the onset of the acute asthma attack. BALB/c mice were immunized and challenged with house dust extract. Twenty-four hours after the last challenge, mice were treated with either systemic Dexa (2.5 mg/kg) or PBS. Normal mice did not receive any immunization, pulmonary challenge, or treatment. All cell counts were performed 48 h after the treatment, and white blood cell differentials were performed after 300 cells were counted. Values represent means $\pm$ SE with $n = 8$ for Dexa or PBS group and $n = 3$ for normal. * $P < 0.05$ or ** $P < 0.01$ compared with PBS treated; †† $P < 0.01$ or ††† $P < 0.001$ compared with normal.

proinflammatory genes and proteins (1). Corticosteroids inhibit the binding of transcription factors such as nuclear factor- κ B and activator protein-1 (7) to DNA. Glucocorticoids also inhibit the synthesis of inflammatory cytokines and chemokines including IL-1 β , IL-2, IL-3, IL-6, IL-8, TNF- α , granulocyte-monocyte colony-stimulating factor, eotaxin, monocyte chemoattractant protein-1, and regulated on activation normal T cell expressed and presumably secreted, which are involved in chemotaxis and apoptosis of inflammatory cells such as eosinophils and lymphocytes (3, 40). Clinical studies showed that treatment of asthma with corticosteroids significantly reduced the number of eosinophils in bronchial mucosa, bronchoalveolar lavage (10, 16, 46), and circulating blood (16) by totally reversing the delayed eosinophil apoptosis in asthma (14, 23).

Pulmonary inflammation and structural changes in the airway induce AHR via the expression of inflammatory mediators including cytokines and chemokines (2, 6). These inflammatory mediators induce remodeling of asthmatic airways through the modification of the smooth muscle contractility, influx of inflammatory cells, vascular permeability, and mucus secretion (6, 22, 25). Several placebo-controlled clinical studies have demonstrated that inhaled or oral corticosteroid treatment ameliorates airway responsiveness (10, 28, 29).

We reported a novel murine model of asthma-like broncho-pulmonary inflammation induced by house dust extract that contained high levels of cockroach allergens and moderate levels of lipopolysaccharide (24). This unique murine model of asthma simulates many features of human asthma, including exacerbation of AHR, pulmonary infiltration of inflammatory cells, and increased recruitment of inflammatory cells and chemokines in bronchoalveolar lavage. Although inhaled, oral, or intravenously administered glucocorticoids are the most effective treatments of asthma (1, 7), very few studies have attempted to develop an animal model to investigate the anti-inflammatory actions of this treatment.

We investigated the effects of dexamethasone, a standard glucocorticosteroid, on the features demonstrated in this model in an effort to expand the understanding of the mechanism of AHR and pulmonary inflammation. Our data clearly demon-

strate that dexamethasone treatment significantly reduced various aspects of pulmonary inflammation in this model following sensitization and intratracheal challenges. Thus our mouse model closely parallels the human studies. Our results of decreased IgE concentrations in blood of dexamethasone-treated animals are consistent with other reports recently published (4, 32, 33).

Our data are similar to previous reports that demonstrated significantly smaller numbers of inflammatory cells and lower myeloperoxidase activity in the mouse model (42, 45) or in a human study (10). The fact that there was no significant difference observed between the number of inflammatory cells in blood of dexamethasone-treated mice and PBS-treated mice with significantly reduced numbers of eosinophils, macrophage, and neutrophils in the lung lavage is suggestive of a downregulation of chemotactic signals and/or reduced expression of cell adhesion molecules for these cells (30). It is noted that the number of neutrophils recruited in the lung was also reduced in the dexamethasone-treated mice, although neutrophils are generally not sensitive to the effects of glucocorticoids (1). However, studies have shown that glucocorticosteroid treatment prolonged the survival time of neutrophils secondary to decreased apoptosis (12, 26). Therefore, if dexamethasone was administered after the onset of an asthma attack, the total number of pulmonary of neutrophils was increased, while the numbers of total leukocytes, eosinophils, and macrophages were decreased. Our previously published data using the same mouse model showed an early influx of neutrophils into the bronchoalveolar lavage fluid (within 12 h after the last challenge), and the numbers peaked 36 h after the second intratracheal challenge. These data are consistent with report by Cox (12), who demonstrated that survival of neutrophils isolated from human blood was significantly increased by glucocorticoids in a dose-dependent manner. These data indicate that glucocorticoids will prevent the recruitment of neutrophils into the lung, but if they are already present, the drugs do not accelerate clearance.

In this study, we also demonstrated that systemic administration of dexamethasone significantly prevented house dust

extract-induced bronchopulmonary hyperreactivity, which is consistent with previous clinical trials (10, 28) and animal models using different allergens (42, 45). However, the effect of dexamethasone on AHR is more dramatically demonstrated when the dexamethasone was administered after the onset of an asthma attack. There are few studies investigating the effects of glucocorticoids delivered after the onset of an asthmatic response in an animal model. Here, dexamethasone was delivered immediately after the 24-h AHR measurement, on the basis of results from the prevention study that showed an AHR peak 24 h after the last intratracheal challenge. Twelve hours after the dexamethasone treatment and 36 h after the last allergen challenge, the bronchopulmonary hyperreactivity in the treated group was significantly improved compared with untreated mice. A similar result was observed in a human study where inhaled budesonide was administered after the onset of the asthmatic response (29).

This represents a very important aspect of our model with respect to the clinical relevance to human asthma, since corticosteroids are the first choice of treatment when an asthmatic patient visits the emergency department for an acute asthma attack (37, 38). In addition, systemic administration of corticosteroids within 1 h of arrival to the emergency department greatly reduces the hospital admission time for asthmatic patients, especially those with more severe asthma, as well as patients who are not being treated with steroids (37). Early treatment also decreases the need for revisiting the clinic for additional treatment, as does the use of β -agonists (38). Our results also suggest that when we pretreat the mice with dexamethasone, the effects of dexamethasone last longer, (i.e., the Penh decrease persists for 24 h), but treatment after the onset of symptoms with dexamethasone was not as effective (i.e., the Penh decrease persists only for 12 h). This supports the current status of clinical management: that it is better to keep the asthma under control rather than only treat acute exacerbations.

Together, these results suggest that administration of dexamethasone not only prevents, but also breaks, the asthmatic pulmonary inflammation in this novel allergic murine model induced by house dust extract immunization and intratracheal instillation. We believe that the murine model of asthma described in the current study closely reproduces the characteristics of human asthma and may be an invaluable tool for further study of the immunopathophysiology of asthma and the interaction with environmental constituents.

ACKNOWLEDGMENTS

The Michigan Center for the Environment & Children's Health (MCECH) is a community-based participatory research initiative investigating the influence of environmental factors on childhood asthma. MCECH involves collaboration among the University of Michigan Schools of Public Health and Medicine, the Detroit Health Department, the Michigan Department of Agriculture, Plant and Pest Management Division, and nine community-based organizations in Detroit (Butzel Family Center, Community Health and Social Services Center, Detroiters Working for Environmental Justice, Detroit Hispanic Development, Friends of Parkside, Kettering/Butzel Health Initiative, Latino Family Services, United Community Housing Coalition and Warren/Conner Development Coalition), and Henry Ford Health System.

GRANTS

This study was supported in part by National Institute of Environmental Health Sciences Grant ES-09589 and Environmental Protection Agency Grant R826710.

REFERENCES

- Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. *Clin Sci (Lond)* 94: 557–572, 1998.
- Barnes PJ. The role of inflammation and anti-inflammatory medication in asthma. *Respir Med* 96: S9–S15, 2002.
- Barnes PJ, Chung KF, and Page CP. Inflammatory mediators of asthma: an update. *Pharmacol Rev* 50: 515–596, 1998.
- Benson M, Strannegard IL, Strannegard O, and Wennergren G. Topical steroid treatment of allergic rhinitis decreases nasal fluid TH2 cytokines, eosinophils, eosinophil cationic protein, and IgE but has no significant effect on IFN- γ , IL-1 β , TNF- α , or neutrophils. *J Allergy Clin Immunol* 106: 307–312, 2000.
- Bice DE, Seagrave J, and Green GHY. Animal model of asthma: potential usefulness for studying health effects of inhaled particles. *Inhal Toxicol* 12: 829–862, 2000.
- Boulet LP, Chakir J, Dube J, Laprise C, Boutet M, and Laviolette M. Airway inflammation and structural changes in airway hyper-responsiveness and asthma: an overview. *Can Respir J* 5: 16–21, 1998.
- Bousquet J, Jeffery PK, Busse WW, Johnson M, and Vignola AM. Asthma from bronchoconstriction to airways inflammation and remodeling. *Am J Respir Crit Care Med* 161: 1720–1745, 2000.
- Busse WW and Lemanske RF Jr. Asthma. *N Engl J Med* 344: 350–362, 2001.
- Campbell EM, Charo IF, Kunkel SL, Strieter RM, Boring L, Gosling J, and Lukacs NW. Monocyte chemoattractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2 $^{-/-}$ mice: the role of mast cells. *J Immunol* 163: 2160–2167, 1999.
- Chanez P, Vignola AM, O'Shaughnessy T, Enander I, Li D, Jeffery PK, and Bousquet J. Corticosteroid reversibility in COPD is related to features of asthma. *Am J Respir Crit Care Med* 155: 1529–1534, 1997.
- Clarke AH, Thomas WR, Rolland JM, Dow C, and O'Brien RM. Murine allergic respiratory responses to the major house dust mite allergen Der p 1. *Int Arch Allergy Immunol* 120: 126–134, 1999.
- Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. *J Immunol* 154: 4719–4725, 1995.
- De Siqueira AL, Russo M, Steil AA, Facincone S, Mariano M, and Jancar S. A new murine model of pulmonary eosinophilic hypersensitivity: contribution to experimental asthma. *J Allergy Clin Immunol* 100: 383–388, 1997.
- Druilhe A, Letuve S, and Pretolani M. [Eosinophil apoptosis in asthma]. *Pathol Biol (Paris)* 48: 566–573, 2000.
- Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, and Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. *Nat Med* 2: 449–456, 1996.
- Gauvreau GM, Wood LJ, Sehmi R, Watson RM, Dorman SC, Schleimer RP, Denburg JA, and O'Byrne PM. The effects of inhaled budesonide on circulating eosinophil progenitors and their expression of cytokines after allergen challenge in subjects with atopic asthma. *Am J Respir Crit Care Med* 162: 2139–2144, 2000.
- Gonzalo JA, Lloyd CM, Kremer L, Finger E, Martinez AC, Siegelman MH, Cybulsky M, and Gutierrez-Ramos JC. Eosinophil recruitment to the lung in a murine model of allergic inflammation. The role of T cells, chemokines, and adhesion receptors. *J Clin Invest* 98: 2332–2345, 1996.
- Hamelmann E, Oshiba A, Loader J, Larsen GL, Gleich G, Lee J, and Gelfand EW. Anti-interleukin-5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitization. *Am J Respir Crit Care Med* 155: 819–825, 1997.
- Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, and Gelfand EW. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. *Am J Respir Crit Care Med* 156: 766–775, 1997.
- Hamelmann E, Takeda K, Oshiba A, and Gelfand EW. Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness—a murine model. *Allergy* 54: 297–305, 1999.
- Hogan SP, Mould A, Kikutani H, Ramsay AJ, and Foster PS. Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. *J Clin Invest* 99: 1329–1339, 1997.
- Holgate ST. Mediator and cellular mechanisms in asthma. The Philip Ellman lecture 1990. *J R Coll Physicians Lond* 24: 304–312, 1990.

23. Kankaanranta H, Lindsay MA, Giembycz MA, Zhang X, Moilanen E, and Barnes PJ. Delayed eosinophil apoptosis in asthma. *J Allergy Clin Immunol* 106: 77–83, 2000.
24. Kim J, Merry AC, Nemzek JA, Bolgos GL, Siddiqui J, and Remick DG. Eotaxin represents the principal eosinophil chemoattractant in a novel murine asthma model induced by house dust containing cockroach allergens. *J Immunol* 167: 2808–2815, 2001.
25. Laitinen LA and Laitinen A. Remodeling of asthmatic airways by glucocorticosteroids. *J Allergy Clin Immunol* 97: 153–158, 1996.
26. Meagher LC, Cousin JM, Seckl JR, and Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. *J Immunol* 156: 4422–4428, 1996.
27. Nemzek JA, Ebong SJ, Kim J, Bolgos GL, and Remick DG. Keratinocyte growth factor pretreatment is associated with decreased macrophage inflammatory protein-2 α concentrations and reduced neutrophil recruitment in acid aspiration lung injury. *Shock* 18: 501–506, 2002.
28. Olivieri D, Chetta A, Del Donno M, Bertorelli G, Casalini A, Pesci A, Testi R, and Foresi A. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. *Am J Respir Crit Care Med* 155: 1864–1871, 1997.
29. Paggiaro PL, Dente FL, Morelli MC, Bancalari L, Di Franco A, Giannini D, Vagaggini B, Bacci E, Fabbri LM, and Giuntini C. Postallergen inhaled budesonide reduces late asthmatic response and inhibits the associated increase of airway responsiveness to methacholine in asthmatics. *Am J Respir Crit Care Med* 149: 1447–1451, 1994.
30. Pitzalis C, Pipitone N, and Perretti M. Regulation of leukocyte-endothelial interactions by glucocorticoids. *Ann NY Acad Sci* 966: 108–118, 2002.
31. Ponath PD, Qin S, Ringler DJ, Clark-Lewis I, Wang J, Kassam N, Smith H, Shi X, Gonzalo JA, Newman W, Gutierrez-Ramos JC, and Mackay CR. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. *J Clin Invest* 97: 604–612, 1996.
32. Pullerits T, Dahlgren U, Skoogh BE, and Lotvall J. Development of antigen-specific IgE after sensitisation with trimellitic anhydride in rats is attenuated by glucocorticoids and cyclosporin A. *Int Arch Allergy Immunol* 112: 279–286, 1997.
33. Pullerits T, Praks L, Sjostrand M, Rak S, Skoogh BE, and Lotvall J. An intranasal glucocorticoid inhibits the increase of specific IgE initiated during birch pollen season. *J Allergy Clin Immunol* 100: 601–605, 1997.
34. Rankin SM, Conroy DM, and Williams TJ. Eotaxin and eosinophil recruitment: implications for human disease. *Mol Med Today* 6: 20–27, 2000.
35. Rothenberg ME. Eosinophilia. *N Engl J Med* 338: 1592–1600, 1998.
36. Rothenberg ME, Luster AD, and Leder P. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. *Proc Natl Acad Sci USA* 92: 8960–8964, 1995.
37. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, and Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. *Cochrane Database Syst Rev* 1: CD002178, 2001.
38. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, and Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. *Cochrane Database Syst Rev* 1: CD000195, 2001.
39. Schneider T and Issekutz AC. Quantitation of eosinophil and neutrophil infiltration into rat lung by specific assays for eosinophil peroxidase and myeloperoxidase. Application in a Brown Norway rat model of allergic pulmonary inflammation. *J Immunol Methods* 198: 1–14, 1996.
40. Schwiebert LM, Beck LA, Stellato C, Bickel CA, Bochner BS, Schleimer RP, and Schwiebert LA. Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. *J Allergy Clin Immunol* 97: 143–152, 1996.
41. Seminario MC and Gleich GJ. The role of eosinophils in the pathogenesis of asthma. *Curr Opin Immunol* 6: 860–864, 1994.
42. Singer M, Lefort J, and Vargaftig BB. Granulocyte depletion and dexamethasone differentially modulate airways hyperreactivity, inflammation, mucus accumulation, and secretion induced by rmIL-13 or antigen. *Am J Respir Cell Mol Biol* 26: 74–84, 2002.
43. Suissa S and Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. *J Allergy Clin Immunol* 107: 937–944, 2001.
44. Tournoy KG, Kips JC, Schou C, and Pauwels RA. Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness. *Clin Exp Allergy* 30: 79–85, 2000.
45. Trifilieff A, El-Hashim A, and Bertrand C. Time course of inflammatory and remodeling events in a murine model of asthma: effect of steroid treatment. *Am J Physiol Lung Cell Mol Physiol* 279: L1120–L1128, 2000.
46. Trigg CJ, Manolitsas ND, Wang J, Calderon MA, McAulay A, Jordan SE, Herdman MJ, Jhalli N, Duddle JM, and Hamilton SA. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. *Am J Respir Crit Care Med* 150: 17–22, 1994.
47. Volmer T. The socio-economics of asthma. *Pulm Pharmacol Ther* 14: 55–60, 2001.
48. Wills-Karp M. Immunologic basis of antigen-induced airway hyperresponsiveness. *Annu Rev Immunol* 17: 255–281, 1999.
49. Zhou D, Chen G, Kim JT, Lee LY, and Kang BC. A dose-response relationship between exposure to cockroach allergens and induction of sensitization in an experimental asthma in Hartley guinea pigs. *J Allergy Clin Immunol* 101: 653–659, 1998.